-1775582746855.png&w=3840&q=75)
tirzepatide w GLP-1/GIP Rx Unlock your potential with this game Weight-Loss Health Assessment Tirzepatide 2.5mg
Description
It contains the active ingredient tirzepatide, which is a GIP receptor and GLP-1 agonist
Mounjaro weight loss injections may increase the risk of developing thyroid tumours, including thyroid cancer
Polycystic Ovary Syndrome (PCOS) Metabolic regulation may improve hormonal balance
Weight loss typically continues beyond trial endpoints if medication continues, though velocity decreases after 6-9 months
Hair loss is listed as a common side effect in the Mounjaro patient information leaflet
Question about your bill
